LY-3084077

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameLY-3084077
Drug Alias NameLY-3084077
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A